CHICAGO – “Lean type 2 diabetes (T2D)” is a diagnosis of exclusion but is also a true entity affecting roughly 10%-20% of people with T2D. That was the message from Kristina Utzschneider, MD, ...
TORONTO — GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide are well known for helping lower blood sugar and supporting weight loss, as well as reducing the risk for heart and kidney ...
This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice. Conclusions: ...
A groundbreaking study has revealed that fotagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, significantly enhances glycemic control in patients with type 2 diabetes (T2D) when combined with ...